News
Drugs Made in America Acquisition Corp. Announces Advisory Team
-
Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”. Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactively pursue the deliverable of a business or combinations that seeks to become a new competitive cost producer of drugs made in America. Onboarding production back to the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America.02/24/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions
Is Drugs Made In America Acquisition Corp. Units (DMAAU) a buy, sell, or hold?
Drugs Made In America Acquisition Corp. Units (DMAAU) can sell. Click on Rating Page for detail.
What is Drugs Made In America Acquisition Corp. Units's stock price?
The price of Drugs Made In America Acquisition Corp. Units (DMAAU) is 10.3301 and it was updated on 2025-07-18 07:00:25.
Is Drugs Made In America Acquisition Corp. Units (DMAAU) overvalued or undervalued?
Currently Drugs Made In America Acquisition Corp. Units (DMAAU) is in undervalued.
SEC Filings
Press Releases
| StockPrice Release |
|---|
DMAAU Ratings Summary
DMAAU Quant Ranking
